Latest news and press releases about Metagenomi, Inc. Common Stock (MGX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases.
Price
| Price | $1.15 |
| Market Cap | $43M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.38 |
| EV / EBITDA | -0.48 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -63.65% |
| Return on Invested Capital | -65.88% |
| Return on Assets | -53.81% |
| Gross Margin | 74.29% |
| Operating Margin | -741.58% |
| Net Margin | -689.20% |
Related companies: ADVM · ALXO · ARTV · ATYR · CNTB · DTIL · IFRX
Explore sector: Healthcare · Biotechnology
More sections of MGX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks